Snake Antivenom Immunoglobulins

Snake Antivenom Immunoglobulins

 

Global burden of snakebites and the shortage of antivenoms

The unavailability of effective snake antivenom immunoglobulins to treat the specific types of snakebite envenoming encountered in various regions of the world has become a critical health issue at the global level. There is an urgent need to ensure the availability of safe, effective, and affordable antivenoms, particularly to those in developing countries, according to the World Health Organization (WHO).

IgY(ΔFc) based Snake Antivenom Immunoglobulins 

Good Biotech has built the proprietary snake antivenom technology platform (as well as the snake venom rapid test kit), which enables to development and optimization of each country’s regional species-specific IgY(ΔFc) antibody-derived Snake Antivenom Immunoglobulins for effective management and control. All kinds of antivenoms are available including:

 

Highly Monospecific Snake Antivenom:

  • Neurotoxic monospecific Snake Antivenom
  • Hematotoxic monospecific Snake Antivenom 

High-Efficacy Polyspecific Snake Antivenom

  • Neurotoxic Polyspecific Snake Antivenom
  • Hematotoxic Polyspecific Snake Antivenom 

According to the results of the studies made by Taiwan Centers for Disease Control, which show that IgY(ΔFc) antibody derived Snake Antivenom Immunoglobulins are much superior to classical equine-based snake antivenoms in terms of Safety, Efficacy, Productivity, and Cost-effectiveness. Moreover, this unique technology enables Fast/Mass Production as well as offers a solution that meets current animal protection trends.

 


The Advantages in Comparison with Classical Equine IgG-based Snake Antivenom Immunoglobulins

  • Higher Neutralization Activity (unit/mg): Neutralizing activity is 10-20 times higher.
  • Excellent Productivity (based on: vials/per Kg body weight of the host animal/ per year): Productivity is 100 times.
  • Rapid Immunological Response (Fast Production): For anti-neurotoxic/ hemorrhagic snake venom, satisfied titer can be collected in 2nd week after inducement.
  • Excellent Immune Response Rate: A 100% immune response rate can be achieved.
  • Safety and Efficiency (Highly Specific): Horse IgG is a powerful immunogen, thus equine derived snake antivenom immunoglobulins suffer from “life-threatening allergic reactions". On the contrary, IgY (ΔFc) based snake antivenom immunoglobulins, derived from egg yolk, are not considered as an allergen. Due to the high neutralizing activity of IgY (ΔFc) antibody, when IgY (ΔFc) based snake antivenom immunoglobulins are used, the victims receive much lower heterogonous protein compared to when IgG-based snake antivenom immunoglobulins are used. IgY (ΔFc) based snake antivenom immunoglobulins are safer and can greatly minimize the risk of serum sickness.
  • Low Cost (Cost Effective): Reducing 90% production cost.
  • Simple Downstream Processing: no need for laborious blood/plasma collection; no need for F(ab’)2 fragment processing. High pure & specific IgY(ΔFc) antibodies are obtained from egg yolks through proprietary technology.
  • Meet the current animal-protection trend: Animal protection groups that are becoming more and more influential in developing countries, condemn animal rearing for serum production. Application of the IgY technology driven by legal regulations in favor of animal protection.

 


The Novel IgY(ΔFc) Snake Antivenom Technology Offers Solutions to Significant Unmet Medical Needs

Good Biotech’s IgY(ΔFc) derived Snake Antivenom Immunoglobulins are expected to provide a Fast, Safe, Effective, Affordable, and Accessible solution in response to the global health need for snake antivenom immunoglobulins. The Primary advantages of this technology including:                                                                                                                                                                                                                                                                                           

  • Manufacturing high quality, efficacy, safety, and low-cost polyspecific snake antivenom immunoglobulins against multiple species in geographic regions.
  •  Manufacturing high quality, efficacy, safety, and low-cost monospecific snake antivenom immunoglobulins against local species.
  • One-Step, Visual Snake Venom Rapid Test Kit: The kit is the one and only diagnostic kit in the world for One-Step Rapid Detection (3-5 minutes) of snake venom for medical emergency use. This new generation Snake Venom Rapid Test Kit is much quicker than current methods (eg. ELISA) and can give victims & healthcare professionals the information needed to act more precisely and effectively in making life-saving decisions.
  • Availability in large-scale & batch-to-batch consistency.
  • The production of lyophilized powder form of IgY(ΔFc) antibody is relatively easy. The powder form of antibody drugs will offer an easy solution, such as more convenience for delivery and more stability for storage especially in those developing countries or tropical areas where refrigerators are not available.
  • Ease of handling and maintenance in large numbers of ducks for immunization with various species venoms. The technology is game-changing enabling affordable, fast & mass production of highly specific snake antivenom immunoglobulins and can make life-saving polyspecific/ monospecific antivenom for various geographic areas of the world.

 

Partnering with Good Biotech

Good Biotech is seeking to collaborate with a leading global pharmaceutical company to further the development of Snake Antivenom Immunoglobulins from bench to bedside.

If you are interested in exploring partnering with us to advance this exciting project, please contact our Partnering Team at partnership@good-biotech.com

 

Related Information: IgY(ΔFc) Antibody-based Snake Venom Rapid Test Kit